OJU1 Stock Chart & Stats
€4.42
€0.14(4.04%)
At close: 4:00 PM EDT
€4.42
€0.14(4.04%)
Day’s Range― - ―
52-Week Range€1.88 - €4.53
Previous CloseN/A
Volume0.00
Average Volume (3M)98.00
Market Cap
€167.69M
Enterprise Value€154.55
Total Cash (Recent Filing)€50.61M
Total Debt (Recent Filing)€733.00K
Price to Earnings (P/E)1.1
Beta0.46
Next Earnings
Jul 14, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.23
Shares Outstanding41,597,355
10 Day Avg. Volume26
30 Day Avg. Volume98
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)59.00
P/FCF Ratio-10.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage gives Oramed financial flexibility while it advances clinical programs and develops its oral delivery technology. A conservative capital structure reduces solvency pressure and leaves greater scope to fund research, pursue collaborations, or manage setbacks without heavy debt servicing demands.
Focused Oral Biologic PlatformA focused platform around oral delivery of biologic medicines provides a coherent long-term development strategy rather than a broad collection of unrelated programs. If clinical development succeeds, oral formulations could support differentiated product opportunities and collaboration interest in diabetes and other therapeutic areas.
Licensing And Collaboration ModelThe licensing-oriented model can provide a route to monetize technology without relying solely on building a commercial sales organization. Upfront and milestone payments may fund development, while royalties could create recurring economics if partnered products ultimately reach market, although timing depends on agreements and progress.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not currently self-funding its activities. Continued clinical development and platform investment may therefore require additional financing, asset monetization, or partnership proceeds, creating funding pressure if cash needs persist or expected inflows are delayed.
Weak Underlying Operating PerformanceLimited revenue and deeply negative EBIT indicate that recent reported net income does not reflect durable operating profitability. This weak earnings quality makes results more volatile and leaves the company dependent on successful development, licensing, or collaboration outcomes before a stable operating base can emerge.
Scilex Repayment ExposureThe extended Scilex repayment schedule leaves Oramed exposed to collection timing and execution risk on a material receivable. The possibility of settling the remaining balance in registered Scilex equity could also produce less predictable value than cash and increase exposure to the counterparty's financial outcomes.
Oramed Pharm News
OJU1 FAQ
What was Oramed Pharmaceuticals’s price range in the past 12 months?
Oramed Pharmaceuticals lowest stock price was €1.88 and its highest was €4.53 in the past 12 months.
What is Oramed Pharmaceuticals’s market cap?
Oramed Pharmaceuticals’s market cap is €167.69M.
When is Oramed Pharmaceuticals’s upcoming earnings report date?
Oramed Pharmaceuticals’s upcoming earnings report date is Jul 14, 2027 which is in 300 days.
How were Oramed Pharmaceuticals’s earnings last quarter?
Oramed Pharmaceuticals released its earnings results on Jul 15, 2026. The company reported €2.372 earnings per share for the quarter, beating the consensus estimate of €0.37 by €2.003.
Is Oramed Pharmaceuticals overvalued?
According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued.
Does Oramed Pharmaceuticals pay dividends?
Oramed Pharmaceuticals does not currently pay dividends.
What is Oramed Pharmaceuticals’s EPS estimate?
Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oramed Pharmaceuticals have?
Oramed Pharmaceuticals has 41,597,355 shares outstanding.
What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?
Oramed Pharmaceuticals reported an EPS of €2.372 in its last earnings report, beating expectations of €0.37. Following the earnings report the stock price went up 0.439%.
Which hedge fund is a major shareholder of Oramed Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:OJU1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oramed Pharm Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
128.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Technical Analysis
―
Whitehawk Therapeutics
―
Quince Therapeutics
―
ALX Oncology Holdings
―
Spruce Biosciences
―